Particle

Welcome to Abcentra™

We are a clinical-stage pharmaceutical company developing new therapeutics for serious and debilitating diseases involving chronic inflammation.

Our pipeline focuses on patient populations at high risk for cardiovascular disease comorbidities because of an underlying chronic inflammatory disorder.

Bullseye Icon

Target Oxidized Lipoproteins

Our products target oxidized lipoproteins, such as low-density lipoprotein (oxLDL) and lipoprotein(a). Oxidized lipoproteins are potent inflammatory mediators that are implicated in several inflammatory diseases.

How It Works

Antibody icon

Treat Inflammatory Disease

Our clinical and preclinical programs are focused on addressing unmet needs in inflammatory diseases including plaque psoriasis, accelerated atherosclerosis and aortic valve stenosis.

Learn More

Recent News

timothy wright board of directors

Timothy Wright Joins Board of Directors

Experienced drug developer and pharma executive, Dr. Timothy Wright, has joined the Abcentra™’s Board of Directors.
Shot of businesspeople having a meeting in an office

Abcentra™ Names Kevin Bacon Chief Executive Officer

Experienced Industry Leader Elevates Research and Development Capabilities, Joins Company At An Important Development Juncture
Bio Viles

Abcentra™ Achieves Manufacturing Milestone

Abcentra™ completes orticumab clinical batch manufacturing in advance of upcoming psoriasis trial